Immunome seeks OK to begin human testing of Covid-19 ‘cocktail,’ expects it to neutralize omicron
Excerpt from the Press Release:
A Chester County biopharmaceutical company has submitted an application with the Food and Drug Administration to begin human testing of its experimental “antibody cocktail” as a Covid-19 treatment.
Exton-based Immunome said Wednesday it expects its antibody cocktail, known as IMM-BCP-01, can neutralize the recently discovered omicron variant.
“Immunome designed its cocktail with multiple points of attack to be resilient in the face of the rapidly evolving virus,” said Matthew Robinson, the company’s senior vice president of research and development.
The new drug candidate contains three monoclonal antibodies that bind to non-overlapping regions of the Covid-19 spike proteins. Spike proteins are sharp bumps that protrude from the surface of the outside of the virus.
Immunome researchers developed the cocktail by working with memory B cells — parts of the body’s immune system — from patients who successfully recovered from their Covid-19 infections to identify a combination of antibodies that are broadly active against the virus.
The company’s long-term plan is to synthetically manufacture the antibodies for use in broad patient populations.
Purnanand Sarma, CEO of Immunome (NASDAQ: IMNM), called the filing of the investigational new drug application for IMM-BCP-01 an important milestone for his company.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?